NO853695L - Isoxazolkarboksylsyrederivater, fremstilling og anvendelse derav. - Google Patents
Isoxazolkarboksylsyrederivater, fremstilling og anvendelse derav.Info
- Publication number
- NO853695L NO853695L NO853695A NO853695A NO853695L NO 853695 L NO853695 L NO 853695L NO 853695 A NO853695 A NO 853695A NO 853695 A NO853695 A NO 853695A NO 853695 L NO853695 L NO 853695L
- Authority
- NO
- Norway
- Prior art keywords
- isoxazole
- alkyl
- dihydro
- indenyl
- tetramethyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- UXYRXGFUANQKTA-UHFFFAOYSA-N 1,2-oxazole-3-carboxylic acid Chemical class OC(=O)C=1C=CON=1 UXYRXGFUANQKTA-UHFFFAOYSA-N 0.000 title description 4
- -1 phosphorus compound Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims description 3
- UBNWPQXLFRMMEI-GQCTYLIASA-N 5-[3-[(e)-3-(3-hydroxy-2-methoxycarbonylphenoxy)prop-1-enyl]phenyl]-1,2-oxazole-3-carboxylic acid Chemical class COC(=O)C1=C(O)C=CC=C1OC\C=C\C1=CC=CC(C=2ON=C(C=2)C(O)=O)=C1 UBNWPQXLFRMMEI-GQCTYLIASA-N 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- LNZGJSJLLKXPKU-UHFFFAOYSA-N 2-azido-1h-imidazole Chemical compound [N-]=[N+]=NC1=NC=CN1 LNZGJSJLLKXPKU-UHFFFAOYSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 90
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000004292 cyclic ethers Chemical class 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-butyl ethyl ether Chemical compound CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 3
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 125000005270 trialkylamine group Chemical group 0.000 description 3
- DALKDFNESXMXHW-UHFFFAOYSA-N 1-(1,1,2,3,3-pentamethyl-2h-inden-5-yl)ethanone Chemical compound C1=C(C(C)=O)C=C2C(C)(C)C(C)C(C)(C)C2=C1 DALKDFNESXMXHW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000004996 alkyl benzenes Chemical class 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001983 dialkylethers Chemical class 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 1
- IHUSZOMIBSDQTB-UHFFFAOYSA-N 1-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C=2C1=CC(C(=O)C)=CC=2 IHUSZOMIBSDQTB-UHFFFAOYSA-N 0.000 description 1
- FSRLCYXRDZIJJT-UHFFFAOYSA-N 1-ethenyl-1,2,3,4-tetrahydronaphthalene Chemical group C1=CC=C2C(C=C)CCCC2=C1 FSRLCYXRDZIJJT-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ZFODSXXPGLNNNN-UHFFFAOYSA-N 5-[2-(3-butyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-2-cyclopropylethenyl]-1,2-oxazole Chemical compound CCCCC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(C1CC1)=CC1=CC=NO1 ZFODSXXPGLNNNN-UHFFFAOYSA-N 0.000 description 1
- ACSKVLHLRHZTSW-UHFFFAOYSA-N 5-[3-methyl-2-(1,1,2,3,3-pentamethyl-2H-inden-5-yl)but-1-enyl]-1,2-oxazole Chemical compound CC1(C(C(C2=CC(=CC=C12)C(=CC1=CC=NO1)C(C)C)(C)C)C)C ACSKVLHLRHZTSW-UHFFFAOYSA-N 0.000 description 1
- VUKRGEXJAFEZPH-UHFFFAOYSA-N 5-[3-methyl-2-(1,1,3,3-tetramethyl-6-propyl-2h-inden-5-yl)but-1-enyl]-1,2-oxazole Chemical compound CCCC1=CC(C(CC2(C)C)(C)C)=C2C=C1C(C(C)C)=CC1=CC=NO1 VUKRGEXJAFEZPH-UHFFFAOYSA-N 0.000 description 1
- PVYCJATVZQVPGI-UHFFFAOYSA-N 5-[3-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)but-1-enyl]-1,2-oxazole Chemical compound CC1(C=2C=CC(=CC=2C(CC1)(C)C)C(=CC1=CC=NO1)C(C)C)C PVYCJATVZQVPGI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- UICZEEWNLRRCGB-SDNWHVSQSA-N CCOC(=O)C1=NOC(=C1)/C=C(\C)/C2=CC3=C(C=C2)C(C(C3(C)C)C)(C)C Chemical compound CCOC(=O)C1=NOC(=C1)/C=C(\C)/C2=CC3=C(C=C2)C(C(C3(C)C)C)(C)C UICZEEWNLRRCGB-SDNWHVSQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 101100468652 Drosophila melanogaster rho-5 gene Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000005328 Viral Cell Transformation Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- IAFBWDJPMMGZHI-UKTHLTGXSA-N [5-[(e)-2-(1,1,2,3,3-pentamethyl-2h-inden-5-yl)prop-1-enyl]-1,2-oxazol-3-yl]methanol Chemical compound C1=C2C(C)(C)C(C)C(C)(C)C2=CC=C1C(\C)=C\C1=CC(CO)=NO1 IAFBWDJPMMGZHI-UKTHLTGXSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001279 adipic acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001727 carbonic acid monoesters Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002995 comedolytic effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000001119 rodenticidal effect Effects 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Oppfinnelsen vedrører fremstilling av nye isoxazolkarboksylsyrederivater .
Fra europeisk OS 98 591 fremgår at vinyltetrahydronafta-liner substituert med en tiofenring har rodentizide egenskaper.
Det ble nå funnet at isoxazolkarboksylsyrederivater med formel I
hvori
1 2
R og R er hydrogenatomer eller metylgrupper
R 3 og R 4hydrogenatomer, C-^^-alkylgrupper eller metoksygrupper
R^ et hydrogen- eller halogenatom eller en C^_^-alkyl- eller C^_g-alkoksygruppe
R et hydrogenatom eller en C-^_g-alkyl eller C-^g-cykloalkyl-gruppe
A en metylen- eller etylenrest, eventuelt substituert med c^_4~alkylgruppe r, og
R 7 tetrazolyl-eller 2-oksazolinresten eller en nitril- eller
8 9 10 C2_10-ketalgruppe eller betyr resten-CH(R )-R eller -CO-R , hvori
R g er et hydrogenatom eller en C,_^-alkylgruppe
9 8 11 12 13 11 R er samme som R eller en rest -OR eller NR R (med R i betydningen av et hydrogenatom, en C, ,-alkyl-, C2_2ø~alkanoyl-
"12 13. eller eventuelt substituert benzoylgruppe og medR<XA>og R i betydningen hydrogenatomer, C^_^-alkyl-, C2_2g~alkanoyl- eller eventuelt substituerte benzoylgrupper)
R<x>^ et hydrogen- eller halogenatom, azido-, imidazol- eller en triazolrest, en C,_4-alkylgruppe eller en rest -OR<14>eller
1516 14
-NR R (med R i betydningen et hydrogenatom, en C1_g-alkyl-, eventuelt med en eller flere hydroksygrupper eller en C1_4~alkoksygruppe substituert C1_<g->alkyl, eventuelt substituerte aryl- eller i aryIdelen substituerte aralkylgrupper, og med R<15>
og R i betydningen hydrogenatomer, C1__g-alkyl-f eventuelt med en eller flere hydroksygrupper substituerte C2_g-alkylrester
eller R"*"^ og R sammen med nitrogenatomet de er bundet til,;i betydningen en aryl- eller tetrazolylgruppe, samt eventuelt deres fysiologiske salter er gode legemiddelvirkestoffer. ;Av forbindelsen med formel I er de foretrukne som har E-konfigurasjon, og i hvilke R 1 og R 2 betyr metylgrupper og A en metylen- eller etylenrest substituert med en metylgruppe. Som halogenatomer for R<x>(^ er fluor og klor foretrukne. Substituerte benzoylgrupper har som substituenter fortrinnsvis halogenatomer - spesielt fluor og klor - og/eller metyl-, metoksy- eller nitrogrupper. ;Som arylgrupper er fenylgrupper foretrukne, hvilke kan være substituert med metyl-, metoksy- eller nitrogruppe; som aralkylgruppe er benzylgruppen foretrukket, hvilken i aryldelen kan være substituert med en metyl- eller metoksygruppe eller med halogen. Som heterocykliske rester kommer fortrinnsvis pyrrolidino-, piperidino- eller morfolinresten i betraktning. ;Typiske eksempler på forbindelser fremstilt ifølge oppfinnelsen er de følgende isoxazolforbindelser, som i isoxazolringens 3-stilling også er substituert med de videre nedenfor førte rester. ;5-t2-(1,1,3,3-Tetrametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl") isoxazol ;5-12-(1,1,2,3,3,-Pentametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl}isoxazol ;5-C2-(5,5,8,8-Tetrametyl-5,6,7,8-tetrahydronaft-2-yl)-1--propenylj isoxazol ;5-[2-(3,8,8-Trimetyl-5,6,7,8-tetrahydronaft-2-yl)-1-prope-nyl]isoxazol ;5-[ 2-(3-Metoksy-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-propenylJisoxazol ;5-f2-(3,5,5,8,8-Pentametyl-5,6,7,8-tetrahydronaft-2-yl)-1--propenylj isoxazol ;5-(2-(3-Etyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2--yl)-1-propenylJ isoxazol ;5-C2-(3-Propyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-l-propenyl}isoxazol 5-[2-(3-butyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2-yl)-l-propenyljisoxazol ;5-C2-(3-(1-Metylety1)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl) -l-propenyl}isoxazol ;5-12-(3-Butyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)1-propenyl] isoxazol ;5- 12-(3- a-Metyletyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl )-1-propenylJ isoxazol ;5-^2-(3-(2-Metylpropyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl) -l-propenyl3 isoxazol ;5-[2-(1,1,3,3,6-Pentametyl-2,3-dihydro-5(1H)-indenyl)-1--propenyl}isoxazol ;5-[2-(6-Ety1-1,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl}isoxazol ;5~r 2-(6-Propyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-inde-nyl )-l-propenyl} isoxazol ;5-C 2-(6-Butyl-l,l,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--l-propenyl}isoxazol ;5-{2-(6-(1-Metyletyl)-1,1,3,3-tetrametyl-2,3-dihydro-5(1H)--indenyl)-1-propenyl}isoxazol ;5-t 2-(6-(2-Metylpropyl)-1,1,3,3-tetrametyl-2,3-dihydro--5(1H)-indenyl)-l-propenyllisoxazol ;5-£2-(1,1,2,3,3,6-Heksametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl}isoxazol ;5-f2-(6-Etyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl ) -1-propenyl isoxazol ;5-L2-(6-Propyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H) - indenyl)-1-propenylJ isoxazol ;5-^2-(6-Butyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl) -1-propenyl]isoxazol ;5-t2-(6-(1-Metyletyl)-1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-inden<y>l)-1-pro<p>en<y>lJ isoxazol ;5-T2-(6-(2-Metylpropyl)-1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl)-l-propenyl]isoxazol ;5-[ 2-(3-Fluor-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-propenyl] isoxazol ;5-£2-(3-Fluor-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-etyenyl] isoxazol ;5-[2-(3-Fluor-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-butenyl]isoxazol ;5-[2-(3-Fluor-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl) -2-cyklopropyl-l-etenyl]]isoxazol ;5- 12-(1,1,2,3,3-Pentamety1-2,3-dihydro-5(1H)-indenyl)-1- -etenyl]isoxazol ;5-f2- (1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-indenyl)-1--etenyl] isoxazol ;5-[2-(5,5,8,8-Tetrametyl-5,6,7,8-tetrahydronaft-2-yl)-1--etenyl] isoxazol ;5-t2-(3,8,8-Trimetyl-5,6,7,8-tetrahydronaft-2-yl)-1-etenyl]-isoxazol ;5-C 2-(3-Metoksy-5,6,7,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-l-etenyl]isoxazol ;5- 12-(3,5,5,8,8-Pentametyl-5,6,7,8-tetrahydronaft-2-yl)-1--etenyl]isoxazol ;5-[2- (3-Ety1-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2--yl)-1-etenyl)isoxazol ;5-[2-(3-Propyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-etenyl]isoxazol ;5-L2-(3-Butyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-etenyl]isoxazol ;5- C2-(3-(1-Metylpropyl)-5,5,8,8-tetramety1-5,6,7,8-tetra-hydronaf t-2-yl ) -1-etenyl]isoxazol ;5-[2-(1,1,3,3,6-Pentametyl-2,3-dihydro-5(1H)-indenyl)-1--etenyl]isoxazol ;5-C2-(6-Etyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--1-etenyl]isoxazol ;5-[2-(6-Propyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-inde-nyl).-l-etenyl] isoxazol ;5-C2-(6-Butyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--1-etenyl] isoxazol 5-[ 2-(6-(1-Metyletyl)-1,1,3,3-tetrematy1-2,3-dihydro-5(1H)--indenyl)-1-etenyl] isoxazol ;5-[2-(6-(2-Metylpropyl)-1,1,3,3-tetrametyl-2,3-dihydro--5(1H)-indenyl)-1-etenyl]isoxazol ;5-[2-(1,1,2,3,3,6-Heksametyl-2,3-dihydro-5(1H)-indenyl)-1--etenyl]isoxazol ;5-C 2-(6-Etyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl)-1-etenyl] isoxazol ;5-[2-(6-Propyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)--indenyl)-1-etenyl]isoxazol ;5-[2-(6-Butyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl ) -1-etenyl] isoxazol ;5-[2-(6-(1-Metyletyl)-1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl)-1-etenyl]isoxazol ;5-[2-(6-(2-Metylpropyl)-1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl-l-etenyl]isoxazol ;5-(2-(1,1,3,3,-Tetrametyl-2,3-dihydro-5(1H)-idenyl)-1--butenyl]isoxazol ;5-[2-(1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-idenyl)-1--butenyl]isoxazol ;5-[2-(5,5,8,8-Tetrametyl-5,6,7,8-tetrahydronaft-2-yl)-1--butenyl]isoxazol ;5-t2-(3,8,8-Trimetyl-5,6,7,8-tetrahydronaft-2-yl)-1-bute-nyl] isoxazol ;5-f2-(3-Metoksy-5,5,8,8-tetrametyl-5,6,7,8-tetrahydro-naf t-2-yl) -l-butenyl] isoxazol ;5-(2-(3,5,5,8,8-Pentametyl-5,6,7,8-tetrahydronaft-2-yl)--1-butenyl]isoxazol ;5-C2-(3-Propyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-butenyl] isoxazol ;5-£2-(3-Butyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-1-butenyl] isoxazol ;5-[2-(3-(1-Metyletyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl)-1-butenylJ isoxazol ;5-C2-(3-(2-Metylpropyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl)-1-butenyl]isoxazol ;5-[2-(1,1,3,3,6-Pentametyl-2,3-dihydro-5(1H)-indenyl)-1--butenyl]isoxazol ;5-[2-(6-Etyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--1-butenyl]isoxazol ;5-L 2-(6-Propyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-inde-nyl )-1-butenyl]isoxazol ;5-£2-(6-Butyl-l,1,3,3-tetramety1-2,3-dihydro-5(1H)-inde-nyl) -1-butenyl]isoxazol ;5-[2-(6-1-Metyletyl)-1,1,3,3-tetrametyl-2,3-dihydro-5(1H)--indenyl)-1-butenyl]isoxazol ;5-C2-(6-(2-Metylpropyl)-1,1,3,3-tetrametyl-2,3-dihydro--5(1H)-indenyl)-1-butenyl isoxazol ;5-[2-(6-(2-Metylpropyl)-1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl)-l-butenyl]isoxazol ;5-C2-(6-(1-Metyletyl)-1,1,2,3,3-pentametyl-2,3-dihydro- -5(1H)-indenyl)-1-butenyl]isoxazol ;5-[2-(6-Butyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl )-1-butenyl}isoxazol ;5-[2-(6-Propyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H) - indenyl)-1-butenyl]isoxazol ;5-[2-(6-Etyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl) -1-butenyl] isoxazol ;5-£2-(l,l,2,3,3,6-Heksametyl-2,3-dihydro-5(1H)-indenyl)-1--propenyl]isoxazol ;5-[2-(1,1,3,3-Tetrametyl-2,3-dihydro-5(1H)-indenyl)-2-cyklo-propyl)-1-etenyl]isoxazol ;5-C2-(1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-indenyl)-2--(cyklopropyl)-1-etenyl]isoxazol ;5- 12-(5,5,8,8-Tetramety1-5,6,7,8-tetrahydronaft-2-yl)-2--(cyklopropyl)-1-etenyl] isoxazol ;5-[2-(3,8,8-Trimetyl-5,6,7,8-tetrahydronaft-2-yl)-2-(cyklo-propyl) -1-etenyl] isoxazol ;5-[2-(3-Metoksy-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-2-(cyklopropyl)-1-etenyl] isoxazol ;5-[2-(3,5,5,8,8-Pentametyl-5,6,7,8-tetrahydronaft-2-yl)-2--(cyklopropyl)-1-etenyl] isoxazol ;5- [2-(3-Etyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2--yl)-2-(cyklopropyl)-1-etylJisoxazol ;5-[2-(3-Propyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-2-(cyklopropyl)-1-etenyl]isoxazol ;5-[2-(3-Butyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-2-(cyklopropyl)-l-eteny]J isoxazol ;5-[2-(3-(1-Metyletyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl) -2-(cyklopropyl)-l-etenyl]isoxazol ;5-[2-(3-(2-Metylpropyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl) -2-(cyklopropyl)-1-etenylJisoxazol ;5-[2-(1,1,3,3,6-Pentametyl-2,3-dihydro-5(1H)-indenyl)-2--(cyklopropyl)-1-etenyl] isoxazol ;5-L2-(6-Etyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--2-(cyklopropyl)-1-etenyl}isoxazol ;5- 12-(6-Propyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-idenyl)--2-(cyklopropyl)-l-etenyl]isoxazol ;5-[2-(6-Butyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--2-(cyklopropyl)-1-etenylj isoxazol ;5-[2-(6-(1-Metyletyl)-1,1,3,3-tetrametyl-2,3-dihydro-5(1H)--indenyl)-2-(cyklopropyl)-l-etenyl]isoxazol 5-[2-(6-(2-Metylpropyl)-1,1,3,3-tetrametyl-2,3-dihydro--5(1H)-indenyl)-2-(cyklopropyl)-1-etenyl]isoxazol 5-[2-(6-(2-Metylpropyl)-1,1,2,3,3-pentamety1-2,3-dihydro--5(1H)-indenyl)-2-(cyklopropyl)-1-etenyl]isoxazol 5-£ 2-(6-(1-Metyletyl)-1,1,2,3,3-pentamety1-2,3-dihydro--5(1H)-indenyl)-2-(cyklopropyl)-1-etenyl]isoxazol 5-[2-(6-Butyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl )-2-(cyklopropyl)-1-etenyl]isoxazol ;5-f 2-(6-Propyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl )-2-(cyklopropyl)-1-etenyl]isoxazol ;5-[2-(6-Etyl-l,1,2,3,3,3-pentamety1-2,3-dihydro-5(1H)-inde-nyl) -2-(cyklopropyl)-1-etenyl]isoxazol ;5-[2-(1,1,2,3,3,6-Heksametyl-2,3-dihydro-5(1H)-indenyl)-2--(cyklopropyl)-1-etenyl]isoxazol ;5-£2-(1,1,3,3-Tetrametyl-2,3-dihydro-5(1H)-indenyl)-3--metyl-buten-l-yl]isoxazol ;5-£2-(1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-indenyl)-3--metyl-buten-l-yl]isoxazol ;5- [2-(5,5,8,8-Tetrametyl-5,6,7,8-tetrahydronaft-2-yl)-3--metyl-buten-l-yl]isoxazol ;5-t2-(3,8,8-Trimetyl-5,6,7,8-tetrahydronaft-2-yl)-3-metyl--buten-l-ylj isoxazol ;5-£2-(3-Metoksy-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft--2-yl)-3-metyl-buten-l-yl]isoxazol ;5-[2-(3-Fluor-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2--yl)-3-metyl-buten-l-yl]isoxazol ;5-£2-(3,5,5,8,8-Pentametyl-5,6,7,8-tetrahydronaft-2-yl)--3-metyl-buten-l-yl]isoxazol ;5-[2-(3-Etyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2--yl)-3-metyl-buten-l-ylJ isoxazol ;5-£.2- (3-Propyl-5 ,5,8, 8-tetrametyl-5,6,7,8-tetrahydronaf t--2-yl)-3-metyl-buten-l-yl]isoxazol ;5-£2-(3-Butyl-5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2--yl)-3-metyl-buten-l-yl]isoxazol ;5-£2-(3-(1-Metyletyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra-hydronaf t-2-yl) -3-metyl-buten-l-ylJ isoxazol 5-t2-(3-(2-Metylpropyl)-5,5,8,8-tetrametyl-5,6,7,8-tetra- ;hydronaft-2-yl)-3-metyl-buten-l-yl]isoxazol ;5-[2-(1,1,3,3,6-Pentametyl-2,3-dihydro-5(1H)-indenyl-3-metyl-buten-l-yl]isoxazol ;5-C2-(6-Etyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--3-metyl-buten-l-yl] isoxazol ;5-[2-(6-Propyl-1,1,3,3-tetrametyl-2,3-dihydro-5(1H)-inde-nyl )-3-metyl-buten-l-yl]isoxazol ;5-[2-(6-Butyl-l,1,3,3-tetrametyl-2,3-dihydro-5(1H)-indenyl)--3-metyl-buten-l-yl]isoxazol ;5-£2-(6-(1-Metyletyl)-1,1,3,3-tetrametyl-2,3-dihydro-5(1H)--indenyl)-3-metyl-buten-l-yl] isoxazol ;5-[2-(6-(2-Metylpropyl)-1,1,3,3-tetramety1-2,3-dihydro--5(1H)-indenyl)-3-metyl-buten-l-yl]isoxazol ;5-[2-(6-(2-Metylpropyl)-1,1,2,3,3-pentamety1-2,3-dihydro--5(1H)-indenyl)-3-metyl-buten-l-yl]isoxazol ;5-[2-(6-(1-Metyletyl)-1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl)-3-metyl-buten-l-yl] isoxazol ;5-[2-(6-Butyl-l,1,2,3,3-pentamety1-2,3-dihydro-5(1H)-inde-nyl) -3-metyl-buten-l-yl]isoxazol ;5-£2-(6-Propyl-l,1,2,3,3-pentamety1-2,3-dihydro-5(1H) - indenyl)-3-metyl-buten-l-yl]isoxazol ;5-£2-(6-Etyl-l,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-inde-nyl) -3-metyl-buten-l-yl]isoxazol ;5-[2-(l,l,2,3,3,6-Heksametyl-2,3-dihydro-5(1H)-indenyl)-3--metyl-buten-l-yl]isoxazol ;5-£2-(5,5,8,8-Tetrametyl-l-metoksy-4-metyl-5,6,7,8-tetra-hydro-naft-2-y1)-1-etenyl]isoxazol ;Disse forbindelser er i isoxazolringens 3-stilling substituert med de følgende typiske rester: 3-Karboksy-, 3-metoksykarbonyl, 3-etoksykarbonyl-, 3-pro-pyloksykarbonyl-, 3-(1-metyl)etoksykarbonyl-, 3-butoksykarbonyl-, 3-oktyloksykarbonyl-, 3-(2-metoksy)etoksykarbonyl-, 3-(2-hyd-roksy)-etoksykarbonyl -, 3-(2,3-dihydroksy)propoksykarbonyl, 3-benzyloksykarbonyl-, 3-cyano-, 3-formyl-, 3-hydroksymetyl-, 3-metyl-, 3-etyl, 3-propyl-, 3-klorformyl-, 3-fluorformyl-, 3-azidoformyl-, 3-acetyl-, 3-metoksymetylT, 3-etoksymetyl-, 3-propyloksymetyl-, 3-butyloksymetyl-, 3-benzyloksymetyl- ; 3-acetoksymetyl-, 3-propionyloksymetyl-, 3-heksadecanoyloksy-metyl-, 3-aminometyl-, 3-benzoyloksymetyl-, 3-(3,4-dimetoksy)- benzoyloksymetyl-, 3-metylaminometyl-, 3-etylaminometyl-, 3-butylaminometyl-, 3-propylaminometyl-, 3-acetyl-, 3-benzoyl-aminometyl-, 3-(4-metoksy)benzoylaminometyl-, 3-acetylamino-metyl-, 3-propionylaminometyl-, 3-palmitoylaminometyl-, 3-N-imi-dazolyl)-karbonyl-, 3-(N-triazolyl)-karbonyl-. ;Forbindelsene som fremstilles ifølge oppfinnelsen kan fremstilles på forskjellig i og for seg kjente måter. For eksempel kan man omsette en karbonylforbindelse med formel (II) ; hvori A, R<1>, R<2>, R<3>,R<4>, r<5>og R<6>har de ovenfor angitte betyd-ninger med en fosforforbindelse med formel (III) ;
17 18 ;hvori R betyr en C^^-alkylgruppe og R en C1_7-alkylgruppe, en karbo-C1_g-alkoksygruppe, eller en C-L_4-alkoksymetyl-C1_4-alkoksymetylgruppe ifølge den såkalte Wittig-Horner-reaksjonen. Man arbeider hensiktsmessig i et løsningsmiddel i nærvær av de vanlige basiske forbindelser for Wittig-Horner-reaksjoner. ;Omsetningen ifølge Wittig-Horner forløper ved en temperatur opptil 100°C, hensiktsmessig ved 20-50°C. Omsetningen kan utføres ved atmosfærisk trykk eller i lukket apparatur under høyere trykk, eventuelt under oppvarming til det angitte temperaturområdet. ;Man kan utføre denne omsetning i nærvær av et fortynnings-eller løsningsmiddel, f.eks. en av de lavere mettede dialkyl-etere, dialkylglykoletere eller cykliske etere, såsom dietyleter, etyl-tert.-butyleter, 1,2-dimetoksyetan, tetrahydrofuran eller dioksan, et aromatisk hydrokarbon, såsom benzen eller et alkyl-benzen, såsom toluen eller xylen, eller et mettet alifatisk hydrokarbon, såsom heksan, heptan eller isooktan, et lavere alifatisk keton, såsom aceton, metyletylketon eller metyliso butylketon, et dialkylformamid, såsom dimetyl eller dietylformamid, eller i blandinger av de nevnte løsningsmidler. Fortrinnsvis anvender man cykliske etere såsom dioksan eller tetrahydrofuran og spesielt dimetylformamid eller blandinger derav, hvor en omsetning generelt forløper ved en temperatur opptil 30°C. ;Omsetningene foretas i nærvær av et deprotoneringsmiddel for fosfatet (III). Egnet er alkalimetallhydrider og alkali-metallamider, spesielt av natrium og kalium, natrium- og kalium-saltene av dimetylsulfoksyd, alkyllitiumforbindelser såsom n-butyllitium eller alkalimetallalkoholater, fortrinnsvis natrium-metanolat og natriumetanolat. ;Isoxazolsyreestrene med formel (I), i hvilke R 7 betyr en karbo-C^_Q-alkoksy-gruppe, overføres hvis dette er ønsket i de frie karboksylsyrer ved esterforsåpning. Omvendt kan den frie syren på kjent måte forestres. ;Hydrolysen forløper på vanlig måte ved generelt opptil 120°C og utføres fortrinnsvis ved romtemperatur. ;Den kan utføres ved atmosfæretrykk eller i lukket apparatur under høyere trykk. ;Hensiktsmessig utføres forsåpningen, henholdsvis forestringen i nærvær av et fortynnings- eller løsningsmiddel, f.eks. en dialkylglykoleter eller cyklisk eter, såsom 1,2-dimetoksyetan, tetrahydrofuran eller dioksan, et lavere alifatisk keton, såsom aceton, metyletylketon eller metylisobutylketon, forestringen spesielt i den påtenkte lavere alifatiske alkohol såsom metanol, etanol, propanol eller isopropanol, eventuelt i nærvær av vann, henholdsvis i blandinger av de nevnte løsningsmidler med vann. ;Foretrukne løsningsmidler er vandige blandinger av etanol og metanol, hvorunder omsetningen utføres ved reaksjonsblandingens kokepunkt. ;Forsåpningen foretas fortrinnsvis i nærvær av alkali, såsom alkalimetallhydroksyder, alkalimetallkarbonater og hydrogenkarbonater, spesielt av natrium og kalium, organiske tertiere baser, såsom pyridin eller lavere trialkylaminer, såsom trimetyl- eller trietylamin i nærvær av vann. Derunder kan den anvendte base anvendes i forhold til esteren i støkiometrisk mengde eller i et lite overskudd. Fortrinnsvis anvendes natrium- eller kaliumhydroksyd. ;Forestringen skjer med fordel under innledning av saltsyre-gass i den alkoholiske reaksjonsblanding. Metylesteren kan også fremstilles ved innvirkning av diazometan på den fri syre. ;Karboksylsyrer med den generelle formel (I), i hvilke da;R 7 står for COOH, kan man overføre i reaktive syrederivater med formel (IV) ; ;
hvori;A, R1, R2, R3, R4, R5, R6 og n har de ovenfor angitte betyd-ninger og X betyr en vanlig, reaktiv rest av et blandet syre-anhydrid eller et halogen. Disse omsettes hensiktsmessig med et løsningsmiddel og eventuelt i nærvær av et syrebindende ;middel med amider ; ;
eller alkoholer HOR<xx>til amider og ;estere. Betegnelsen X i formelen (IV) betyr et halogenatom, spesielt klor eller også brom, eller f.eks. N-hydroksysuccinimid-resten. Disse omsetninger av IV forløper ved en temperatur på opptil 50°C ved atmosfæretrykk eller i lukket apparatur under høyere trykk. ;Man kan utføre disse omsetninger i nærvær av et fortynnings-eller løsningsmiddel, f.eks. en lavere mettet dialkyleter, dialkylglykoletere eller cykliske etere, såsom dietyleter, etyl-tert.-butyleter, 1,2-dimetoksyetan, tetrahydrofuran eller dioksan, et aromatisk hydrokarbon, såsom benzen eller en alkylben-zen, såsom toluen eller xylen, eller et mettet alifatisk hydrokarbon, såsom héksan, heptan eller isooktan, et lavere alifatisk keton, såsom aceton, metyletylketon eller metylisobutylketon, ;et dialkylformamid, såsom dimetyl- eller dietylformamid, eller i blandinger av de nevnte løsningsmidler. Fortrinnsvis anvender man lineære eller cykliske etere såsom dietyleter eller tetra-hydrof uran samt spesielt dimetylformamid, hvorunder omsetningen generelt forløper ved en temperatur opptil 30°C. ;Normalt foretas omsetningen i nærvær av en base som syrebindende middel. Egnede baser er alkalimetallkarbonater, hyd rogenkarbonater, spesielt av natrium og kalium, organiske tertiære baser såsom pyridin eller lavere trialkylaminer, såsom trimetyl- eller trietylamin. Derunder anvendes basen i forhold til anvendt isoxazolsyrehalogenid i støkiometrisk mengde eller i lite overskudd. ;En annen mulighet for fremstilling av forbindelsene går ut fra de tilsvarende syrer med formel IV, hvorunder X i dette tilfellet står for OH, og man foretar omsetningen i nærvær av et aktiverende, vannavspaltende middel for karboksylgruppen i ;et løsningsmiddel med aminer ; ;
Som vannavspaltende aktiverende reagenser kan de vanlige reagenser ved peptidsyntesen anvendes, slik som de som f.eks. er beskrevet av Schroder og Lubke i "The Peptides", band I, Academic Press, N.Y., 1965, s. 77 til 128. Det generelle prin-sipp ved omsetningen består i aktiveringen av karbonylgruppen, f.eks. ved behandling av et karbodiimid, såsom N,N'-dicyklo-heksylkarbodiimid, eller ved forbigående dannelser av syre-azidet, et blandet anhydrid (f.eks. med kullsyremonoestere), eller en aktivert ester (f.eks. p-nitrofenylesteren) eller et heterocyklisk amid (f.eks. et imidazolid) av den tilsvarende karboksylsyre (IV). ;Behandlingen av en forbindelse med aktivert karboksylgruppe ;med aminer ; fører da til de ønskede forbindelser. Akti-verings- og sammenknytningsreaksjonene kan utføres i løsnings-midler, fortrinnsvis i N,N-dimetylformamid, tetrahydrofuran, dioksan, metylenklorid, nitrometan, acetonitril, dimetylsulfoksyd, N,N-dimetylacetamid og heksametylfosforsyretriamid. En egnet temperatur for begge trinn, dvs. reaksjonen av syre med koblingsmidlet og reaksjonen av det aktiverte mellomprodukt med aminene ;
ligger f.eks. mellom 20 og 100°C. Man kan ;derunder enten gå frem trinnvis, idet man isolerer det aktiverte mellomproduktet før tilsetningen av aminet, og med fordel idet man bringer reaksjonspartnerne i rekkefølge uten isolering av ;mellomtrinn til omsetning. Ved en foretrukket sammenknyttings-metode anvender man N,N-karbonyldiimidazol og arbeider i dimetylformamid, hvorunder reaksjonstemperaturen for begge trinn ligger på 20 til 60°C. ;For fremstilling av de tilstrebede amider, i hvilke R<x>~<*>betyr hydrogen, er den direkte aminolyse av estere (med resten -OR<14>), med primære aminerH2N-R<15>ved romtemperatur uten løs-ningsmiddel, eller eventuelt i nærvær av et organisk løsnings-middel, såsom alkoholer, etere, dialkylformamider eller blandinger av disse løsningsmidler foretrukket.
Et karboksylsyrehalogenid med formel (IV), fortrinnsvis syrekloridet, kan ved omsetning med 2-aminoetanol eller 2-amino--2-metylpropanol-l og etterfølgende cyklisering overføres i et oksazolinderivat med formel (I).
En karboksylsyre, en karboksylsyreester eller et karboksyl-syreamid med formel (I) kan på i og for seg kjent måte reduseres til alkoholene, henholdsvis aminene med formel (I). Med fordel utføres reduksjonen ved hjelp av et metallhydrid eller alkali-metallhydrid i nærvær av et egnet løsningsmiddel. Som metallhydrider anvendes fortrinnsvis komplekse metallhydrider såsom litiumaluminiumhydrid eller diisobutylaluminiumhydrid. Som løs-ningsmiddel anvendes ved arbeidet med litiumaluminiumhydrid etere, såsom dietyletere, dioksan eller tetrahydrofuran. Ut-fører man imidlertid reduksjonen med diisobutylaluminiumhydrid eller et alkoksynatriumaluminiumhydrid, foretrekkes anvendelsen av hydrokarboner såsom heksan eller toluen.
Et amin eller en alkohol med formel (I) kan på i og for
seg kjent måte med et alkanoylhalogenid eller -anhydrid, et aralkylhalogenid eller -anhydrid eller et aroyl eller hetero-aroylhalogenid eller anhydrid hensiktsmessig i et inert fortynnings- eller løsningsmiddel, f.eks. et lavere alifatisk keton, såsom aceton, metyletylketon eller metylisobutylketon,
et dialkylformamid såsom dimetylformamid eller dietylformamid, eller med overskudd acyleringsmiddel som fortynnings- eller løsningsmiddel, overføres i de tilstrebede amider av estere med formel (I). Hensiktsmessig utføres omsetningen i nærvær av en base som syrebindende middel i et temperaturområde som ligger mellom -20°C og reaksjonsblandingens kokepunkt. Egnede baser er alkalimetallkarbonater, hydrogenkarbonater, hydroksyder
eller alkoholater, spesielt av natrium og kalium, basiske oksyder, såsom aluminiumoksyd eller kalsiumoksyd, organiske tertiære baser, såsom pyridin, eller lavere trialkylaminer, såsom trimetyl eller trietylamin. Derunder kan basene anvendes i katalytisk mengde eller i støkiometrisk mengde, henholdsvis i lite overskudd i forhold til det anvendte alkyleringsmiddel.
En alkohol med formel (I) kan omsettes med alkylhalogenider R<xx->J, R<lx->Br eller Rlx-Cl i nærvær av alkalimetallhydrider, fortrinnsvis natriumhydrid eller i nærvær av alkyllitiumforbindelser, fortrinnsvis n-butyllitium i et organisk løsnings-middel såsom tetrahydrofuran, dioksan, 1,2-dimetoksyetan, metyl-tert.-butyleter eller ved anvendelse av natriumhydrid eller i dimetylformamid i et temperaturområde mellom -10°C og 4 0°C til en eter med formel (I).
En alkohol med formel (I) kan med egnede oksydasjonsmidler, fortrinnsvis mangan(IV)-oksyd, eventuelt på et uorganisk bære-materiale såsom kiselgel eller aluminiuoksyd oksyderes til et aldehyd med formel (I). Med fordel arbeider man i et inert organisk løsningsmiddel, f.eks. et hydrokarbon såsom heksan eller i en eter, såsom f.eks. tetrahydrofuran eller i blandinger av de nevnte løsnings- og fortynningsmidler i temperaturområdet mellom -10°C og 30°C. Den nødvendige reaksjonstid er i det vesentlige avhengig av oksydasjonsaktiviteten til det anvendte mangan(IV)-oksyd.
Forbindelsen med formel (I) kan ha enhetlig cis- eller trans-struktur eller være blandinger av de to E/Z-isomere.
En isomerblanding kan dessuten ikke utelukkes ved de foran-nevnte omsetninger. Den i slike tilfeller, f.eks. resulterende blanding av forbindelsen med formel (I) kan bestemmes kvantita-13
tivt ved HPLC-analyse eller ved en CNMR-spektral analyse, og den ønskede isomere eventuelt isoleres ved fraksjonert krystal-liser ing eller kromatografi med f.eks. kiselgelsøyler eller preparativ HPL-kromatografi i ren isomerform.
Noen av forbindelsene fremstilt ifølge foreliggende oppfinnelse har et surt hydrogenatom og kan derfor på vanlig måte overføres i et fysiologisk fordragelig, godt vannløselig salt. Egnede salter er f.eks. ammonium, alkalimetall, spesielt av natrium, kalium og litium, jordalkalimetallsalter, spesielt av kalsium eller magnesium samt salter med egnede organiske baser, såsom med lavere alkylaminer, f.eks. metylamin eller etylamin, med substituerte lavere alkylaminer, spesielt hydroksysubsti-tuert alkylaminer såsom dietanolamin, trietanolamin eller tris--(hydroksymetyl)-aminometan, piperidin eller morfolin.
Aminer med formel (I) fremstilt ifølge oppfinnelsen lar seg på i og for seg kjent måte overføre i deres syreaddisjons-salter med fysiologisk fordragelige syrer. Som vanlig fysiologisk fordragelige organiske eller uorganiske syrer kommer f.eks. saltsyre, hydrogenbromid, fosforsyre éller svovelsyre i betraktning, og som organiske syrer, f.eks. oksalsyrer, maleinsyrer, fumarsyrer, melkesyre, vinsyre, eplesyre, sitronsyre, salicyl-syre, adipinsyre eller benzosyre, og kan finnes i Fortschritten der Arzneimittelforschung Band 10, side 224-225, Birkhauser Verlag, Basel og Stuttgart, 1966.
Forbindelsen fremstilt ifølge oppfinnelsen og deres fysiologiske fordragelige salter kan på grunn av deres farmakologiske egenskaper anvendes ved topisk og systemisk terapi og også pro-fylakse av prekanzeroser og karzinomer i huden, slimhinner og indre organer samt ved topiske og systemisk terapi av akne, psoriasis og andre dermatologiske sykdommer som henger sammen med patologisk forandret horndannelse samt for behandling av revmatiske sykdommer, spesielt av slike av betennelses- eller degenerativ type, som angriper ledd, muskler, sener og andre deler av bevegelsesapparatet. Et foretrukket indikasjonsområde er ved siden av terapi av dermatologiske sykdommer den profylak-tiske og terapeutiske behandling av prekanzeroser og tumorer.
De farmakologiske virkninger kan f.eks. vises i de etter-følgende forsøksmodeller: Forbindelsene fremstilt ifølge foreliggende oppfinnelse opphever på marsvin treakealvev keratini-seringen som følger in vitro av vitamin-A-mangel. Denne kera-tinisering hører til karcinogenesens tidlige fase, som i en lignende teknikk in vivo etter igangsetning ved kjemiske forbindelser inhiberes med energirik stråling eller etter viral celletransformasjon med forbindelsen med formel (I). Denne metodikk er beskrevet i Cancer Res. 36, 964-972 (1976) eller Nature 250, 64-66 (1974) og Nature 253, 47-50 (1975).
Dertil inhiberes formeringshastigheten til bestemte ond-artet forandrede celler av forbindelsen fremstilt ifølge oppfinnelsen. Denne metodikk er å lese i J. Nati. Cancer Inst.
60, 1035-1041 (1978),Experimental Cell Research 117, 15-22
(1978) og Proe. Nati.Acad. Sei. USA 77, 2936-2940.
Den antiartritiske virkningen til forbindelsen fremstilt ifølge oppfinnelsen kan på vanlig måte bestemmes i dyreeksperi-menter i Adjuvans-Arthritis-modellen. Den dermatologiske aktivitet, f.eks. for behandling av akne, kan blant annet påvises med den komedolytiske aktivitet og evnen til å redusere antall cyster i modellen Rhino-mus.
Denne metode er beskrevet av L.H. Kligman et al i The Journal of Investigative Dermatology 73, 354-358 (1979) og av J.A. Mezick et al. i "Models of Dermatology" (Ed. Maibach, Lowe), Vol. 2, s. 59-63, Karger, Basel 1985).
Forsøkssubstansen ble påført hele ryggpartiet til Rhino-mus i en egnet bærer (100 ill) en gang daglig i fem på hverandre følgende dager pr. uker. Omtrent 72 timer etter den siste behandling ble rygghuden fjernet og plassert 18 timer ved 4-6°C
i 0,5% eddiksyre. Deretter ble en ca. 2 x 5 cm 2 stor flate skåret ut, epidermis skrellet av, lagt på et objektglass (med den dermale side oppad)og spylt vannfri ved hjelp av alkohol/- xelen inntil epidermis syntes gjennomsiktig. Prøven ble fiksert ved overdekning med Permount og vurdert mikroskopisk. Diamete-ren av 10 utriculi ble målt i 5 fritt valgte felt og derav behandlet man ved sammenligning med den ubehandlede kontrollgruppe den gjennomsnittlige reduksjon av utriculustverrsnittet. Den følgende tabell viser de oppnådde resultater.
Følgelig inneholder et terapeutisk middel for topisk og systemisk anvendelse en forbindelse med formel (I) samt vanlige bærestoffer eller fortynningsmidler. Fremstillingen av det terapeutiske midlet eller preparat skjer med de . vanlige flytende eller faste bærestoffer eller fortynningsmidler og de på vanlig måte anvendte farmasøytisk tekniske hjelpestoffer avhengig av denønskede applikasjonsmåte og med en dosering som er egnet for anvendelsen på vanlig måte, f.eks. ved blanding av virkestoffet med de vanlige faste eller flytende bære- og hjelpestoffer i slike preparater.
Midlene kan tilsvarende gis oralt, parenteralt eller topisk. Slike preparater er f.eks. tabletter, filmtabletter, drageer, kapsler, piller, pulvere, løsninger eller suspensjoner, infu-sjons- eller injeksjonsløsninger samt pastaer, salter, geler, kremer, lotioner, puddere, løsninger eller emulsjoner og sprays.
De terapeutiske midler kan inneholde forbindelsen som skal anvendes ved lokal anvendelse i 0,001 til 1%-ig konsentrasjon, fortrinnsvis i 0,001 til 0,l%ig konsentrasjon, og ved systemisk anvendelse fortrinnsvis i en enkelt dose på 0,1 til 50 mg, og kan gis daglig i en eller flere doser avhengig av sykdommens art og styrke.
Vanlig anvendte farmasøytiske tekniske hjelpestoffer er f.eks. for lokal anvendelse alkoholer, såsom isopropanol, oksetylert ricinusolje, oksetylert hydrogenert ricinusolje, poly-akrylsyre, glycerolmonostearat, paraffinolje, vaseliner, ull-fett, polyetylenglykol 400, polyetylenglykol 400-stearat samt etoksylert fettalkohol, for systemiske anvendelser melkesukker, propylenglykol og etanol, stivelse, talkum, polyvinylpyrrolidon. Preparatene kan eventuelt tilsettes et antioksydasjonsmiddel, f.eks. tokoferol samt butylert hydroksyanisol eller butylert hydroksytoluen eller smaksforbedrende tilsetninger, stabilise-ringsmidler, emulgeringsmidler, glidemidler osv. Forutsetningen er at alle stoffer som anvendes ved fremstillingen av det farma-søytiske preparatet er toksikologisk ubetenkelige og fordragelige sammen med de anvendte virkestoffer.
De følgende eksempler illustrerer oppfinnelsen.
Eksempel 1
(E)-5-f2-(1,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl]isoxazol-3-karboksylsyreetylester
Til en suspensjon av 300 ml tetrahydrofuran og 9 g 80%-ig natriumhydrid, som forut med petroleter var befridd for 20%-ig paraf f inandel, ble i løpet av 30 min. dryppet en r, Løsning" av--87 , 4g dietyl(3-karboetoksyisoxazol-5)metylenfosfonat i 200 ml tetra-hydrof uran ved ca. 40°C. Deretter rørte man videre i ytterlige-re 15 minutter og dryppet i løpet av 10 minutter til en løsning av 50,6 g 5-acetyl-l,1,2,3,3-pentametylindan i 200 ml tetra-hydrof uran. Etter to timer ble satsen helt i 2 1 isvann og ekstrahert tre ganger med dietyleter. Ekstraktene ble vasket nøytrale med vann, tørket over natriumsulfat og befridd for flyktige bestanddeler på rotasjonsfordamper. Det dannede faste stoff ble gnidd med 100 ml metanol. Etter tørking i en nitrogenatmosfære fikk man tilbake 31,8 g (E)—5— f2—(1,1,2,3,3--pentametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl] -isoxazol-3--karboksylsyreetylester med smp. 90-91°C.
<X>H-NMR-Spektre viser at det dreier seg om den rene trans-konfigurasjonsisomere tittelforbindelse.
Eksempel 2
(E)-5- 11-(1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl] isoxazol-3-karboksylsyre
6 g (E)-5-(2-(l,1,2,3,3-Pentametyl-2,3-dihydro-5(lH)-inde-nyl)-1^-propenyl] isoxazol-3-karboksylsyreetylester fikk stå med 1,2 g kaliumhydroksyd i en blanding av 400 ml etanol og 20 ml vann 6 timer ved romtemperatur. Etter at hele reaksjonsmassen var overført i 1.liter vann surgjorde man med 2 N saltsyre, fil-trerte den erholdte fylling fra og gnidde med 100 ml metanol. Etter ny filtrering av krystallisatet og tørking i nitrogenstrøm fikk man tilbake 3,8 g (E)-5-f2-(1,1,2,3,3-pentametyl-2,3-dihyd-ro-5(1H)-indenyl)-1-propenyl] isoxazol-3-karboksylsyre, med smp. 1.68-169°C. XH-NMR-Spektret viser at det dreier seg om den rene isomere tittelforbindelse med transkonfigurasjon, hvilket også er revers-fase HPLC-analyse (RP-C18; 150 bar; etanol/20% vann) bekrefter. Eksempel 3
(E)-5-f2-(1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl]isoxazol-3-karboksylsyreamid 4,5 g (E)-5-n-(l,l,2,3,3-Pentametyl-2,3-dihydro-5(lH)--indenyl)-1-propenyl]isoxazol-3-karboksylsyreetylester ble rørt med 150 ml konsentrert ammoniakløsning i 200 ml etanol i 10 timer. Etter overføring av hele reaksjonsmassen i 500 ml vann ble den erholdtefylling filtrert fra og vasket med litt iskald metanol. Etter tørking fikk man tilbake 3,6 g (E)-5-[2-(1,1,2 , - 3,3-pentametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl]isoxazol--3-karboksylsyreamid, smp. 196-197°C. Eksempel 4
(E)-5-f2-(1,1,2,3,3-Pentametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl]-N-(2,3-dihydroksypropyl)-isoxazol-3-karboksylsyre-amid.
3,7 g (E)-5-r2-(l,1,2,3,3-Pentametyl-2,3-dihydro-5(lH)--indenyl)-1-propenyl]isoxazol-3-karboksylsyreetylester fikk stå med 25 ml l-amino-2,3-propandiol i 70 ml etanol i 10 timer. Etter overføring av hele reaksjonsmassen til 500 ml vann surgjorde man med 2 N saltsyre. Den erholdte fylling filtreres fra og vaskes med litt metanol. Etter tørking i nitrogenstrøm får man tilbake 2,1 g (E)-5-C2-(1,1,2,3,3-pentamety1-2,3-dihydro--5(1H)-indenyl)-1-propenyl] -N-(2,3-dihydroksypropyl)-isoxazol--3-karboksylsyreamid smp. 150-151°C.
Eksempel 4a
Analogt med eksempel 4 får man ut fra (E)-5-[ 2-(1,1,2,3,3--pentametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl]isoxazol-3--karboksylsyreetylester og etanolamin og det ønskede produkt (E)-5-f2-(1,1,2,3,3,-pentametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl]-N-(2-hydroksyetyl)-isoxazol-3-karboksylsyreamid,
smp. 143-144°C.
Forbindelsene som er angitt i den etterfølgende tabell ble fremstilt som beskrevet i eksempel 1.
Eksempel 18
Analogt med den arbeidsmetoden som er beskrevet i eksempel 1 fremstilte man ut fra 5-acetyl-l,1,2,3,3-pentametylindan og dietyl(3-metylisoxazol-5-)metylenfosfonat (E)-3-metyl-5-[2--(1,1,2,3,3-pentamety1-2,3-dihydro-5(1H)-indenyl)-l-propenyl3-isoxazol, smp. 120 - 121°C.
På samme måte ble de etterfølgende substanser syntetisert.
Eksempel 2 2
Analogt med den arbeidsmåte som er beskrevet i eksempel 1 fremstilte man ut fra 6-acetyl-l,1,4,4-tetrametyltetralin og dietyl(3-metoksymetylisoxazolyl-5)metylenfosfonat (E)-3-Metoksymetyl-5-[2-(5,5,8,8-tetrametyl-5,6,7,8-tetrahydronaft-2-yl)-1-propenylJisoxazol, med smp. 72-73°C.
Eksempel 23
(E)-3-Hydroksymetyl-5-f2-(5,5,8,8-tetrametyl-5,6,7,8-tetra-hydro-naft-2-yl)-1-propenyl)isoxazol
Til en omrørt suspensjon av 1 g litiumaluminumhydrid i
150 ml dietyleter drypper man en løsning av 5 g (E)-5-[2--(5,5,8,8-tetrametyl-5,6,7,8-tetrahydro-naft-2-yl)-1-propenyl] isoxazol-3-karboksylsyreetylester i 50 ml dietyleter. Etter 3 timer blander man dråpevis med 200 ml av en 10%-ig vandig vinsyreløsning og ekstraherer flere ganger med dietyleter.
De forenede organiske faser vaskes nøytrale og tørkes med vann-fritt natriumsulfat. Den krystallinske rest som er tilbake etter inndamping omkrystalliseres fra 25 ml metanol. Men får således 2,3 g av tittelforbindelsen, smp. 138-139°C.
Eksempel 24
Analogt med den arbeidsmetode som er beskrevet i eksempel 2 3 fremstilte man ut fra (E)-5-[2-(1,1,2,3,3-pentametyl-2,3-di-hydro-5(1H)-indenyl)-1-propenyl]isoxazol-3-karboksylsyreetylester (E)-3-Hydroksymetyl-5-[2-(1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl)-1-propenyl]isoxazol.
Eksempel 25
(E)-3-Acetoksymetyl-5-f 2-(1,1,2,3,3-pentametyl-2,3-dihydro--5(1H)-indenyl)-1-propenyl]isoxazol
En løsning av 4,9 g (E)-3-hydroksymetyl-5-t2-(1,1,2,3,3--pentametyl-2,3-dihydro-5(1H)-indenyl)-1-propenyl] isoxazol i 25 ml dietyleter og 10 ml pyridin ble dråpevis blandet med 4,7 ml acetylklorid ved 0°C til 5°C. Deretter rørte man videre 3 timer ved romtemperatur, man helte så på vann og ekstraherte med dietyleter. Den organiske fasen ble behandlet med 1 N saltsyre, vasket nøytral med vann og tørket over natriumsulfat. Det faste stoff som var tilbake etter inndampning av løsningen, ble omkrystallisert fra 20 ml etanol. Derved fikk man 5,2 g av tittelforbindelsen, smp. 91 - 92°C.
Eksempel 26
(E)-3- N-(3-Hydroksy-4-karboksyfenylamino)tiooksometylkar-bamoyl -5- 2-(1,1,2,3,3-pentametyl-2,3-dihydro-5(1H)-indenyl)--1-propenyl isoxazol
I en løsning av 5 g (E)-5- 2-(1,1,2,3,3-pentametyl-2,3-di-hydro-5(1H)-indenyl)-1-propenyl isoxazol-3-karboksylsyre, 30 ml tetrahydrofuran og 1,4 ml pyridin dryppet man 1,2 ml tionyl-klorid. Etter 45 minutter ved romtemperatur tilsatte man denne blandingen 1,6 g kaliumrodanid i 15 ml aceton og etter ytter-ligere 45 minutter 2,8 g 4-amino-2-hydroksybenzosyre i 30 ml tetrahydrofuran.
Etter 8 timer ble hele reaksjonsmassen helt i en løsning av 400 ml metanol og 400 ml vann. Det erholdte faste stoff filtrerer man fra og vasker det på filteret i rekkefølge med metanol og n-heptan. Etter tørking i nitrogenstrøm blir 4,3 g av tittelforbindelsen tilbake, smp. 221-222°C.
Claims (2)
1. Fremgangsmåte ved fremstilling av isoxazolkarboksylsyrederivater med formel I
hvori
R 1 og R <2> betyr hydrogenatomer eller metylgrupper 3 4
R og R hydrogenatomer, C-, ,-alkylgrupper eller metoksygrupper, R 5et hydrogen- eller halogenatom eller en C^ _^ -alkyl eller C-, _6~alkoksygruppe
R et hydrogenatom eller en C-L _6 -alkyl eller C3 _6 -cykloalkyl-gruppe
A en metylen- eller etylenrest, eventuelt substituert med c^ _4~ alkylgruppe, og
7 8 9 IQ R oksazolinresten eller resten -CH(R )-R eller -CO-R hvori
R g betyr et hydrogenatom eller en C,_^ -alkylgruppe
q o X —j , 2 to i R det samme som R eller en rest -Or <H> eller NR R (med R i betydning et hydrogenatom, en C-, _4-alkyl-, C„_9n -alkanoyl-12 13 .
eller eventuelt substituert benzoylgruppe og med R og R i betydningen hydrogenatomer,C^ _^ -alkyl-, C2 _2 g~ alkanoyl- eller eventuelt substituerte benzoylgrupper)
R <x> (^ et hydrogen- eller halogenatom, azido-, imidazol- eller 14 triazolresten, en C^_^-alkylgruppe eller en rest -OR eller
-NR<15>R<16> (medR<14> i betydning et hydrogenatom, en C1 _g-alkyl-, eventuelt med en eller flere hydroksygrupper eller en c^ _4~ alkoksygruppe substituert C,_o -alkyl-, eventuelt substituert15 aryl- eller i aryIdelen substituert aralkylgruppe, og med R og R 1 fi i betydning hydrogenatomer, C1 _g-alkyl-, eventuelt med en eller flere hydroksygrupper substituerte C9 _fi -alkylrester eller R <15> og R 16 betyr sammen med nitrogenatomet de er bundet til en heterocyklisk rest
samt eventuelt deres fysiologisk fordragelige salter, karakterisert ved at man omsetter en karbonylforbindelse med formel (II)
hvori A, R <1> , R <2> , R <3> ,R<4> ,R<5> og R <6> har de foran angitte betydnin-ger, med en fosforforbindelse med formel (III)
17 18
hvori R betyr en C^^ -alkylgruppe og R står for en alkylgruppe, en karbo- <C>1 _g-alkoksygruppe, eller en C-L _4 -alkoksy-metyl-C1 _4 -alkoksymetylgruppe ifølge den såkalte Wittig-Horner-reaksjon, og de således erholdte forbindelser om ønsket deretter overfø res i andre forbindelser med formel I.
2. Fremgangsmåte ifølge krav 1, ved fremstilling av (E)-5-^2-
-(3-fluor-5,5,8,8-tetramety1-5,6,7,8-tetrahydronaft-2-yl)-1-propenyljisoxazol-3-karboksylsyre,
karakterisert ved at man anvender tilsvarende substituerte utgangsmaterialer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19843434947 DE3434947A1 (de) | 1984-09-22 | 1984-09-22 | Isoxazolcarbonsaeure-derivate, ihre herstellung und verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
NO853695L true NO853695L (no) | 1986-03-24 |
Family
ID=6246163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO853695A NO853695L (no) | 1984-09-22 | 1985-09-20 | Isoxazolkarboksylsyrederivater, fremstilling og anvendelse derav. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0176033A3 (no) |
JP (1) | JPS6193172A (no) |
AU (1) | AU4783585A (no) |
DE (1) | DE3434947A1 (no) |
FI (1) | FI853626L (no) |
HU (1) | HU193343B (no) |
IL (1) | IL76453A (no) |
NO (1) | NO853695L (no) |
ZA (1) | ZA857273B (no) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1209606B (it) * | 1984-12-13 | 1989-08-30 | Zambon Spa | Processo per la preparazione di isossazoli 3,5-disostituiti. |
ZW10287A1 (en) * | 1986-07-15 | 1988-01-13 | Hoffmann La Roche | Tetrahydronaphthaline and indane derivatives |
US5084476A (en) * | 1986-07-15 | 1992-01-28 | Hoffmann-La Roche Inc. | Tetrahydronaphthalene and indane derivatives |
US5602130A (en) * | 1987-03-20 | 1997-02-11 | Allergan | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5264578A (en) * | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
AT389106B (de) * | 1987-10-08 | 1989-10-25 | Warner Lambert Co | Neue styrylpyrazole, isoxazole und analoge davon, welche als 5-lipoxygenaseinhibitoren wirksam sind,sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen |
US5272156A (en) * | 1989-09-19 | 1993-12-21 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5183827A (en) * | 1989-09-19 | 1993-02-02 | Allergan, Inc. | Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity |
US5264456A (en) * | 1989-12-29 | 1993-11-23 | Allergan, Inc. | Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity |
US5324840A (en) | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US6172115B1 (en) | 1993-02-11 | 2001-01-09 | Allergan Sales, Inc. | Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid |
US5475022A (en) * | 1993-10-18 | 1995-12-12 | Allergan, Inc. | Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity |
US5426118A (en) * | 1993-12-30 | 1995-06-20 | Allergan, Inc. | [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity |
US5498755A (en) * | 1994-08-23 | 1996-03-12 | Chandraratna; Roshantha A. | Disubstituted aryl and heteroaryl imines having retinoid-like biological activity |
US5618931A (en) * | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5618943A (en) * | 1994-12-29 | 1997-04-08 | Allergan | Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5556996A (en) * | 1994-12-29 | 1996-09-17 | Allergan | Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity |
US5489584A (en) * | 1994-12-29 | 1996-02-06 | Allergan, Inc. | Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5514825A (en) * | 1994-12-29 | 1996-05-07 | Allergan, Inc. | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity |
US5599967A (en) * | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
US5543534A (en) * | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5648514A (en) | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5534641A (en) * | 1994-12-29 | 1996-07-09 | Allergan | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
US6025388A (en) * | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
US5616712A (en) * | 1995-05-16 | 1997-04-01 | Allergan | Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity |
US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
AU7598596A (en) * | 1995-11-01 | 1997-05-22 | Allergan, Inc. | Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity |
US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US5688957A (en) * | 1995-12-29 | 1997-11-18 | Allergan | (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5808124A (en) * | 1996-06-21 | 1998-09-15 | Allergan | O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US5747542A (en) * | 1996-06-21 | 1998-05-05 | Allergan | Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity |
US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5741896A (en) | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US5760276A (en) * | 1997-03-06 | 1998-06-02 | Allergan | Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
US6037488A (en) * | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) * | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3624079A (en) * | 1969-10-20 | 1971-11-30 | Upjohn Co | 5-(phenylstryl)-3methylisoxazoles |
DK158947C (da) * | 1982-07-06 | 1991-01-21 | Hoffmann La Roche | Tetrahydronaphthalin-,benzofuran- og benzothiophenderivater, fremstilling og anvendelse deraf samt rodenticid indeholdende saadanne derivater |
-
1984
- 1984-09-22 DE DE19843434947 patent/DE3434947A1/de not_active Withdrawn
-
1985
- 1985-09-19 EP EP85111836A patent/EP0176033A3/de not_active Withdrawn
- 1985-09-20 HU HU853548A patent/HU193343B/hu not_active IP Right Cessation
- 1985-09-20 FI FI853626A patent/FI853626L/fi not_active Application Discontinuation
- 1985-09-20 NO NO853695A patent/NO853695L/no unknown
- 1985-09-22 IL IL76453A patent/IL76453A/xx unknown
- 1985-09-23 ZA ZA857273A patent/ZA857273B/xx unknown
- 1985-09-24 AU AU47835/85A patent/AU4783585A/en not_active Abandoned
- 1985-09-24 JP JP60209009A patent/JPS6193172A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL76453A (en) | 1989-01-31 |
AU4783585A (en) | 1986-04-10 |
EP0176033A3 (de) | 1987-08-26 |
JPS6193172A (ja) | 1986-05-12 |
HU193343B (en) | 1987-09-28 |
FI853626L (fi) | 1986-03-23 |
HUT39435A (en) | 1986-09-29 |
FI853626A0 (fi) | 1985-09-20 |
DE3434947A1 (de) | 1986-04-03 |
ZA857273B (en) | 1986-05-28 |
EP0176033A2 (de) | 1986-04-02 |
IL76453A0 (en) | 1986-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO853695L (no) | Isoxazolkarboksylsyrederivater, fremstilling og anvendelse derav. | |
NO161910B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tetralinderivater. | |
CA1338939C (en) | Vinylphenol derivatives, their preparation and their use | |
EP0176034B1 (de) | Diarylacetylene, ihre Herstellung und Verwendung | |
CA1076134A (en) | Process for preparing phenylacetic acid ester derivatives | |
US4058558A (en) | Aromatic keto acids and derivatives having analgetic, antiinflammatory, and hypocholesterolemizing action | |
US4008323A (en) | Method of reducing cholesterol using certain aromatic keto acids | |
JPH02270835A (ja) | ジフエニルヘテロアルキル誘導体 | |
EP0176035B1 (de) | 1-substituierte Tetralinderivate, ihre Herstellung und Verwendung | |
AU621453B2 (en) | Oxidized diphenylheteroalkanes, the preparation and use thereof | |
US20040198980A1 (en) | Selective rxr ligands | |
NO171159B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive polycykliske heterocyklusderivater | |
AU637098B2 (en) | Substituted pyrrole compounds and their applications in pharmacy | |
CH633250A5 (de) | Verfahren zur herstellung von neuen polyprenylderivaten. | |
US4234742A (en) | Bis-(aryloxycarboxylic acid) compounds | |
RU1826967C (ru) | Способ получени фенилгидразонов, а также их физиологически переносимых солей | |
US4362891A (en) | Alkanoic acid derivatives | |
Taylor et al. | 1, 3-Dipolar cycloaddition of nitrile oxides with 1, 4-dihydropyridines and conformational analysis of isoxazolo [5, 4-b] pyridines | |
FI81346C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara -/10-oxi-4h-benso/4,5/cyklohepta/1,2-b/ tiofen-4-yliden/karboxylsyraderivat. | |
NO853694L (no) | Vinyltetrazolylfenylderivater, fremstilling og anvendelse derav. | |
NO128222B (no) | ||
US5194664A (en) | Aromatic keto compounds, the preparation thereof, and drugs and cosmetics containing these | |
SU873871A3 (ru) | Способ получени производных фенилуксусной кислоты | |
JPS6039273B2 (ja) | ナフタレン誘導体およびその製造方法 | |
US4385004A (en) | Esters of ortho-allylphenol useful for the preparation of arylacetic acid derivatives |